RSS

Biogen

In a surprise announcement, pharma company Biogen has revealed it is set to pursue FDA approval for its Alzheimer’s drug aducanumab, which was previously discontinued in March earlier this year. Read more

News

Technology group Fujifilm will acquire a large-scale biologics manufacturing site from biotech player Biogen for approximately $890 million, the company has announced. Read more

News

Biotechnology company Biogen has announced it will acquire clinical-stage gene therapy company, Nightstar Therapeutics for approximately $800 million. Read more

News

Positive topline results from the Phase II clinical study assessing an anti-amyloid beta protofibril antibody in patients with early Alzheimer’s disease have been revealed by Eisai and Biogen. Read more

News

An option exercise to further reduce the royalty rates payable on potential future sales of aducanumab — a Phase III investigational treatment for early Alzheimer’s disease — has been announced by Biogen and Neurimmune. Read more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. Read more

News

Biogen and AbbVie have announced the voluntary global withdrawal of Zinbryta (daclizumab) — a treatment for relapsing multiple sclerosis (MS) — in the best interests of patient safety. Read more

News

Here, Michael Merges, Catalent Biologics, and Brian Fahie, Biogen, discuss the growing need for partners who can provide niche technologies to accelerate development projects. Read more

, Opinion

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion, recommending that biosimilar Imraldi be granted marketing authorisation. Read more

News

The CHMP has given a positive opinion recommending that Biogen’s treatment for patients with spinal muscular atrophy (SMA), SPINRAZA (nusinersen), be granted marketing authorisation. Read more

News

According to business intelligence provider GBI Research, pharmaceuticals company Roche will be the biggest mover in the neurodegenerative drugs space over the next five years. Read more

News

A clinical trial of a new drug shows promising results for those suffering early-stage Alzheimer’s Read more

News

Pfizer, AstraZeneca, Merck and other Big Pharma companies have signed up to a consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s Read more

News

Calchan has announced an established management team, led by Brenda Reynolds, CEO, which has a successful track record of building UK-based companies, creating value for investors and commercialisng IP. Read more

News